We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current CSMYF market cap is 3.89B. The company's latest EPS is JPY 600.9508 and P/E is 0.16.
| Year End 31 May 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 611.14B | 684.4B | 726.42B | 755.41B | 827.7B |
| Operating Income | 24.78B | 29.09B | 33.15B | 29.8B | 30.13B |
| Net Income | 19.19B | 21.44B | 27.16B | 23.16B | 23.8B |
| Year End 31 May 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 273.56B | 320.28B | 341.32B | 363.05B | 420.97B |
| Total Liabilities | 147.27B | 174.61B | 170.74B | 172.55B | 209.9B |
| Total Equity | 126.29B | 145.68B | 170.58B | 190.51B | 211.07B |
| Year End 31 May 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 34.38B | 65.46B | 27.88B | 32.19B | 54.43B |
| Investing | -30.04B | -26.96B | -19.38B | -43.72B | -49.11B |
| Financing | -6.98B | -5.41B | -5.51B | -6.22B | 3.25B |
| Market Cap | 3.89B |
| Price to Earnings Ratio | 0.16 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.08 |
| Price to Book Ratio | 0.02 |
| Dividend Yield | - |
| Shares Outstanding | 39.6M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 5.58 (6.58%) |
| Company Name | Cosmos Pharmaceutical Corporation (PK) |
| Address |
4fs kan daiichi fukuoka bldg 2-10-1 fukuoka, fukuoka 812-0013 |
| Website | https://www.cosmospc.co.jp |
| Industry | retail trade (svc) (SDF) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
